Literature DB >> 6690067

Aminoglutethimide and warfarin. A new important drug interaction.

P E Lønning, S Kvinnsland, G Jahren.   

Abstract

Aminoglutethimide (AG) has recently been introduced for endocrine therapy in patients with advanced breast and endometrial cancer. In this study two patients being treated with both AG and the anticoagulant agent warfarin are described. An important drug interaction was observed, resulting in a decrease in the anticoagulant effect of warfarin. This was shown by means of thrombotest measurements and pharmacokinetic evaluation of warfarin. A 3- to 5-fold increase in warfarin clearance was found. This interaction is probably due to an AG-promoted induction of hepatic microsomal enzymes accelerating warfarin metabolism.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6690067     DOI： 10.1007/bf00255901

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN： 0344-5704            Impact factor:   3.333


  19 in total

Review 1.  Protein binding of coumarin anticoagulants in disease states.

Authors:  K Bachmann; R Shapiro
Journal:  Clin Pharmacokinet       Date:  1977 Mar-Apr       Impact factor: 6.447

2.  Kinetics of warfarin absorption in man.

Authors:  A Breckenridge; M Orme
Journal:  Clin Pharmacol Ther       Date:  1973 Nov-Dec       Impact factor: 6.875

3.  Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration.

Authors:  P B Andreasen; E S Vesell
Journal:  Clin Pharmacol Ther       Date:  1974-12       Impact factor: 6.875

4.  Successful medical adrenalectomy with amino-glutethimide. Role of altered drug metabolism.

Authors:  R J Santen; A Lipton; J Kendall
Journal:  JAMA       Date:  1974 Dec 23-30       Impact factor: 56.272

5.  Effect of phenobarbital and glutethimide on biological half-life of warfarin.

Authors:  M Corn
Journal:  Thromb Diath Haemorrh       Date:  1966-12-01

6.  The features of hepatic enzyme induction with glutethimide in man.

Authors:  L Jackson; M Homeida; C J Roberts
Journal:  Br J Clin Pharmacol       Date:  1978-12       Impact factor: 4.335

7.  High-pressure liquid chromatographic analysis of drugs in biological fluids I. Warfarin.

Authors:  T D Bjornsson; T F Blaschke; P J Meffin
Journal:  J Pharm Sci       Date:  1977-01       Impact factor: 3.534

8.  Serum protein binding as a determinant of warfarin body clearance and anticoagulant effect.

Authors:  A Yacobi; J A Udall; G Levy
Journal:  Clin Pharmacol Ther       Date:  1976-05       Impact factor: 6.875

9.  A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer.

Authors:  R J Santen; T J Worgul; E Samojlik; A Interrante; A E Boucher; A Lipton; H A Harvey; D S White; E Smart; C Cox; S A Wells
Journal:  N Engl J Med       Date:  1981-09-03       Impact factor: 91.245

10.  Medical adrenalectomy with aminoglutethimide in the management of advanced breast cancer.

Authors:  R M Murray; P Pitt; G Jerums
Journal:  Med J Aust       Date:  1981-02-21       Impact factor: 7.738
View more
  13 in total

1.  Single-dose and steady-state pharmacokinetics of aminoglutethimide.

Authors:  P E Lønning; J S Schanche; S Kvinnsland; P M Ueland
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

Review 2.  Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer.

Authors:  P E Lønning; S Kvinnsland
Journal:  Drugs       Date:  1988-06       Impact factor: 9.546

3.  The effect of anastrozole on the single-dose pharmacokinetics and anticoagulant activity of warfarin in healthy volunteers.

Authors:  R A Yates; J Wong; M Seiberling; M Merz; W März; M Nauck
Journal:  Br J Clin Pharmacol       Date:  2001-05       Impact factor: 4.335

Review 4.  Clinically significant drug interactions with the oral anticoagulants.

Authors:  M D Freedman; A G Olatidoye
Journal:  Drug Saf       Date:  1994-05       Impact factor: 5.606

5.  Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer.

Authors:  B P Haynes; M Jarman; M Dowsett; A Mehta; P E Lønning; L J Griggs; A Jones; T Powles; R Stein; R C Coombes
Journal:  Cancer Chemother Pharmacol       Date:  1991       Impact factor: 3.333

Review 6.  First generation aromatase inhibitors--aminoglutethimide and testololactone.

Authors:  G Cocconi
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

Review 7.  Antineoplastic agents. Drug interactions of clinical significance.

Authors:  E van Meerten; J Verweij; J H Schellens
Journal:  Drug Saf       Date:  1995-03       Impact factor: 5.606

8.  Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings.

Authors:  P E Lønning; S Kvinnsland; T Thorsen; P M Ueland
Journal:  Clin Pharmacokinet       Date:  1987-12       Impact factor: 6.447

9.  Aminoglutethimide enzyme induction: pharmacological and endocrinological implications.

Authors:  P E Lønning
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 10.  Aromatase inhibitors in malignant diseases of aging.

Authors:  D C Johannessen; P E Lønning
Journal:  Drugs Aging       Date:  1992 Nov-Dec       Impact factor: 3.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.